BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1686 related articles for article (PubMed ID: 2108063)

  • 1. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
    Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
    Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
    Heikinheimo O; Gordon K; Williams RF; Hodgen GD
    Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
    Greene KE; Kettel LM; Yen SS
    Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
    Cameron ST; Thong KJ; Baird DT
    Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to intermittent RU486 in women.
    Spitz IM; Croxatto HB; Salvatierra AM; Heikinheimo O
    Fertil Steril; 1993 May; 59(5):971-5. PubMed ID: 8486197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.
    Carr BR; Parker CR; Madden JD; MacDonald PC; Porter JC
    J Clin Endocrinol Metab; 1979 Sep; 49(3):346-9. PubMed ID: 224073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
    Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
    Croxatto HB; Salvatierra AM; Romero C; Spitz IM
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of ovulation by low-dose mifepristone (RU 486).
    Ledger WL; Sweeting VM; Hillier H; Baird DT
    Hum Reprod; 1992 Aug; 7(7):945-50. PubMed ID: 1331167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.